A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Cancer Clinical Trials
Adjuvant Stage III Colon
Breast - Adjuvant
Endocrine Therapy +/- Chemo with 1-3 Positive Nodes, Hormone Receptor (+) and Her2 (2) with Recurrence Score (RS) of 25 or Less.
Breast - Adjuvant Node (+) or High Risk Node (-), HER2 Low
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
Breast - Advanced ER (+) HER2 (-)
A randomized, multicenter, double-blind, placebo-controlled phase 3 trial of fulvestrant (Fasdolex®) with or without PD-0332991 (Palbociclib) +/- Goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy.
Breast - Bone Pain
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim.
Breast - Bone Pain Education
Randomized, Single-Blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim.
Breast - Low or Intermediate Levels of HER2 Protein
A Multicenter, Multinational, Prospective, Randomized, Double-Blind, Controlled Phase 3 Study to Assess the Efficacy and Safety of NeuVaxTM in Subjects with Early Stage NP Breast Cancer whose Tumors Express Low or Intermediate Levels of the HER2 Protein.
Breast - Metastatic, BRCA1 & BRACA2
A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer.
Breast - Operable, HER2 (+)
A randomized, multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
ASBrS Nipple Sparing Mastectomy Registry.
A randomized, phase II, multicenter placebo-controlled study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer.
Colorectal - Advanced
An open-label, multi-center, randomized phase 1B/2 study of PF-05212384 (PI3K inhibitor) plus 5-Fluorouracil-Leucovorin-Iriniotecan (FOLFIRI) versus Bevacizumab plus FOLFIRI in metastatic colorectal cancer.
City of Hope Registry
Molecular Genetics Studies of Cancer Patients and Their Relatives
Head and Neck
A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
Lung - Metastatic
A randomized, phase III study comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without concurrent Cetuximab in patients with advanced non-small cell lung cancer (NSCLC).